Cargando…
Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study
OBJECTIVE: To evaluate the real-world safety and efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. METHODS: This prospective multicenter observational study registered all patients with mC...
Autores principales: | Suzuki, Kazuhiro, Matsubara, Nobuaki, Kazama, Hirotaka, Seto, Takeshi, Tsukube, Shoko, Matsuyama, Hideyasu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933873/ https://www.ncbi.nlm.nih.gov/pubmed/31361807 http://dx.doi.org/10.1093/jjco/hyz108 |
Ejemplares similares
-
Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m(2)) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study
por: Matsuyama, Hideyasu, et al.
Publicado: (2020) -
Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan
por: Matsuyama, Hideyasu, et al.
Publicado: (2023) -
Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer
por: Kazama, Hirotaka, et al.
Publicado: (2022) -
Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021) -
Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)